This presentation describes a clinical trial, conducted in Ethiopia, Kenya and Sudan, of the use of sodium stibogluconate (SSG), paromomycin or the 2 drugs in combination to treat visceral leishmaniasis (VL). It was found that such a trial was feasible in a rural setting, and there were comparatiively few safety concerns, but in eastern Sudan the dose of paromomycin was inadequate and had to be increased.
Presentation from ‘Improved Treatments for Visceral Leishmaniasis – Status of Ongoing Studies’. Symposium held at World Leish 4, Lucknow, India, 4 February 2009.
New treatments for visceral leishmaniasis in Africa – The story so far.